Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483563 | 1.00 | RORC (0.49) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL4483556 | 1.00 | RORC (0.49) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL4944424 | 1.00 | RORC (0.49) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL27688526 | 1.00 | RORC (0.49) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL16109014 | 0.90 | ENPP2 (0.51) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL15141289 | 0.90 | ENPP2 (0.51) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL14934468 | 0.90 | ENPP2 (0.51) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL14610186 | 0.90 | ENPP2 (0.51) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL16070094 | 0.88 | RORC (0.55) | RORCMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL3993928 | 0.88 | RORC (0.55) | RORCMEN1KMT2AHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1553084-A1 | PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | OPRL1, OXTR, OPRM1 | RORC 2424/4885MEN1 3581/4885KMT2A 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.